Please login to the form below

Not currently logged in
Email:
Password:

J&J pain drug delayed

Johnson & Johnson has been informed that additional information for its extended-release tapentadol is needed before US approval

The US Food and Drug Administration (FDA) has informed Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) that additional information is needed before the federal agency can act on the company's New Drug Application (NDA) for extended-release tapentadol. The drug is being reviewed for the management of moderate to severe chronic pain in adults.

The company said that the Complete Response Letter issued by the FDA seeks additional information on the conversion of the formulation of the drug used in the clinical trials to a different formulation that is intended to reduce the potential for abuse by making the tablet harder to break or crush. The FDA is not requesting additional clinical studies, J&JPRD noted.

"We will engage FDA in active discussions as quickly as possible so that we can address the requests in the Complete Response Letter," Juergen Haeussler, therapeutic area head, analgesia, at J&JPRD, said in a written statement. "We remain fully committed to bringing tapentadol ER to patients experiencing chronic pain as quickly as possible."

The drug is a long-acting version of the company's Nucynta pain therapy, which was approved by the FDA in late 2008 and is marketed in the US by the PriCara division of J&J's Ortho-McNeil-Janssen Pharmaceuticals. J&JPRD submitted the NDA for the extended-release formulation on December 1, 2009 on behalf of Ortho-McNeil-Janssen, which will market the extended-release product if it is approved.


 

4th October 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics